Healthcare Equipment and Supplies
Company Overview of InSightec Ltd.
InSightec Ltd. develops and distributes the Exablate platform that provides non-invasive treatments for various oncology and gynecology indications. The company offers a neurosurgery solution that includes Exablate Neuro, a non-invasive and image-guided personalized thalamotomy for movement disorders and pain, treated through an intact skull; MR guided Focused (MRgFUS), a non-invasive thermal ablation technique to relieve symptoms caused by uterine fibroids, as well as destroys uterine fibroid tissue using a thermal effect; and a non-invasive and non-ionizing treatment that uses focused ultrasound waves to ablate the target treatment with minimal damage to surrounding tissues. It also provid...
5 Nahum Heth Street
Tirat Carmel, 39120
Founded in 1999
Key Executives for InSightec Ltd.
Executive Chairman and Chief Executive Officer
President and Chief Commercial Officer
Founder and Vice Chairman
Chief Financial Officer and Vice President
Vice President of Operations and Quality
Compensation as of Fiscal Year 2016.
InSightec Ltd. Key Developments
InSightec Signs Non-Exclusive Cooperation Agreement with Siemens Healthcare GmbH
Aug 15 16
InSightec announced that it signed a non-exclusive cooperation agreement with Siemens Healthcare GmbH, to develop compatibility between InSightec's MRI guided Focused Ultrasound Systems (MRgFUS) and Siemens MRI scanners with the intention to expand the MRgFUS market globally. Under the agreement, the parties will cooperate regarding the performance of R&D, integration, testing and approving the compatibility of the parties' systems. Each party shall be solely responsible, at its own cost, to obtain the regulatory approval for its systems, and InSightec shall be solely responsible, at its sole cost, to obtain the regulatory approval for the combined system. Each party shall bear all of its internal and external costs relating to its performance under the agreement, except that InSightec shall reimburse Siemens an amount agreed upon in the agreement for its R&D costs. The agreement also determines that each party shall act independently in the marketing and sales of its component portion of the combined system, and determines the amount InSightec shall pay Siemens for sales of the combined systems. The term of the agreement is five years from the first commercial sale of the combined system and shall automatically renew for additional one-year periods, unless either party has provided a notice for its non-renewal or of its termination.
INSIGHTEC Receives FDA Approval for its Exablate Neuro System for the Non-Invasive Treatment of Essential Tremor
Jul 12 16
INSIGHTEC announced that the FDA has approved its Exablate Neuro system for the non-invasive treatment of essential tremor (ET) in patients who have not responded to medication. Exablate Neuro uses focused ultrasound waves to precisely target and ablate tissue deep within the brain with no incisions or implants. The treatment is done under Magnetic Resonance Imaging (MRI) guidance for real time treatment monitoring. The patient experiences immediate tremor improvement following the outpatient procedure. The treatment carries minimal risk of infection, bleeding or other surgical complications. The treatment requires a single session with no anesthesia, allowing patients to quickly return to normal activity. Essential tremor is the most common movement disorder, affecting more than 5 million people in the United States, and millions more worldwide. Hand tremor is the most common symptom, but tremors can also affect the head, arms, voice, legs, and torso. For these patients, performing everyday tasks presents a challenge and impacts their quality of life. This approval by the FDA was based on clinical data from a randomized, double-blind, multi-center clinical study designed to evaluate the safety and efficacy of non-invasive thalamotomy with MRgFUS. A total of 76 patients were enrolled in the study and randomly assigned to receive the Exablate treatment (56 patients) or the sham procedure (20 patients), the exact same procedure but without any ultrasound energy. Patients in the placebo treatment arm were later allowed to undergo an Exablate Neuro treatment. Patients treated with the Exablate Neuro showed nearly a 50% improvement in their tremors and motor function three months after treatment compared to their baseline score. Patients in the control group had no improvement, and some experienced a slight worsening after the sham procedure before they crossed over into the treatment group. A year following the procedure, the patients who underwent the Exablate Neuro procedure retained a 40% improvement in these scores compared to baseline.
InSightec Image Guided Treatment Ltd. Signs Non-Binding Memorandum of Understanding with International Imaging Company
Apr 17 16
Elbit Medical Technologies Ltd. announced that its subsidiary InSightec Image Guided Treatment Ltd. had signed a non-binding memorandum of understanding with an international imaging company for joint adaptation of their devices.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 31, 2015